

Rosa Marina Melillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6813681/publications.pdf>

Version: 2024-02-01

87
papers

6,622
citations

61984

43
h-index

62596

80
g-index

124
all docs

124
docs citations

124
times ranked

7001
citing authors

#	ARTICLE	IF	CITATIONS
1	PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. <i>Cell</i> , 1990, 60, 557-563.	28.9	905
2	Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. <i>Nature Medicine</i> , 2002, 8, 1136-1144.	30.7	644
3	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1068-1081.	8.2	231
4	HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. <i>Cancer Cell</i> , 2006, 9, 459-471.	16.8	226
5	Mast cells have a protumorigenic role in human thyroid cancer. <i>Oncogene</i> , 2010, 29, 6203-6215.	5.9	190
6	Thyroid cancer and inflammation. <i>Molecular and Cellular Endocrinology</i> , 2010, 321, 94-102.	3.2	186
7	RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. <i>European Journal of Endocrinology</i> , 2006, 155, 645-653.	3.7	176
8	Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8/Akt/Slug pathway. <i>Oncogene</i> , 2015, 34, 5175-5186.	5.9	176
9	A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma. <i>Cancer Research</i> , 2007, 67, 10148-10158.	0.9	167
10	Minireview: RET: Normal and Abnormal Functions. <i>Endocrinology</i> , 2004, 145, 5448-5451.	2.8	160
11	BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 1623-1629.	7.0	160
12	Molecular Mechanisms of RET Activation in Human Cancer. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 116-121.	3.8	137
13	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1068-1081.	8.2	126
14	Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade. <i>Molecular and Cellular Biology</i> , 2001, 21, 4177-4187.	2.3	123
15	Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. <i>Oncogene</i> , 2004, 23, 5958-5967.	5.9	119
16	Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(4-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1897-1902.	3.6	115
17	Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. <i>Oncogene</i> , 1998, 16, 2435-2445.	5.9	112
18	Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma. <i>American Journal of Pathology</i> , 2002, 160, 247-254.	3.8	103

#	ARTICLE	IF	CITATIONS
19	Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer. <i>Cancer Research</i> , 2007, 67, 11821-11829.	0.9	100
20	Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. <i>Pharmacological Research</i> , 2015, 102, 184-191.	7.1	97
21	Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer. <i>Cancer Research</i> , 2011, 71, 1792-1804.	0.9	87
22	Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation. <i>Molecular and Cellular Biology</i> , 2001, 21, 2485-2495.	2.3	86
23	The Neuron-Specific Rai (ShcC) Adaptor Protein Inhibits Apoptosis by Coupling Ret to the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. <i>Molecular and Cellular Biology</i> , 2002, 22, 7351-7363.	2.3	84
24	The ret/ptc1 Oncogene Is Activated in Familial Adenomatous Polyposis-Associated Thyroid Papillary Carcinomas1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1003-1006.	3.6	82
25	Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E832-E840.	3.6	73
26	Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5270-5278.	3.6	71
27	The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. <i>Oncogene</i> , 2015, 34, 3826-3838.	5.9	69
28	Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. <i>Oncogene</i> , 2003, 22, 4569-4577.	5.9	67
29	Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. <i>Oncogene</i> , 2006, 25, 5467-5474.	5.9	66
30	<i>Helicobacter pylori</i> Hp(2â€“20) Promotes Migration and Proliferation of Gastric Epithelial Cells by Interacting with Formyl Peptide Receptors In Vitro and Accelerates Gastric Mucosal Healing In Vivo. <i>Journal of Immunology</i> , 2009, 183, 3761-3769.	0.8	60
31	XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. <i>Oncogene</i> , 2009, 28, 937-949.	5.9	59
32	The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. <i>Oncogene</i> , 2001, 20, 209-218.	5.9	57
33	Molecular defects in thyroid carcinomas: Role of the RET oncogene in thyroid neoplastic transformation. <i>European Journal of Endocrinology</i> , 1995, 133, 513-522.	3.7	56
34	Biochemical and molecular characterization of the novel BRAFV599Ins mutation detected in a classic papillary thyroid carcinoma. <i>Oncogene</i> , 2006, 25, 4235-4240.	5.9	56
35	AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , 2015, 6, 23281-23296.	1.8	55
36	Tyrosines 1015 and 1062 Are<i>in Vivo</i>Autophosphorylation Sites in Ret and Ret-Derived Oncoproteins¹. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3898-3907.	3.6	54

#	ARTICLE	IF	CITATIONS
37	Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness. <i>Clinical Cancer Research</i> , 2005, 11, 8019-8027.	7.0	53
38	RET/Papillary Thyroid Carcinoma Oncogenic Signaling through the Rap1 Small GTPase. <i>Cancer Research</i> , 2007, 67, 381-390.	0.9	50
39	Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2013, 168, 1545-1547.	1.7	50
40	The ret/ptc1 Oncogene Is Activated in Familial Adenomatous Polyposis-Associated Thyroid Papillary Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1003-1006.	3.6	49
41	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. <i>Oncogene</i> , 2003, 22, 246-255.	5.9	46
42	RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. <i>Oncogene</i> , 2001, 20, 6973-6982.	5.9	45
43	Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells. <i>Cancer Research</i> , 2004, 64, 3823-3829.	0.9	45
44	The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins. <i>Cancer Research</i> , 2006, 66, 6280-6287.	0.9	44
45	Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation. <i>Journal of Biological Chemistry</i> , 2013, 288, 17481-17494.	3.4	44
46	Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. <i>Oncogene</i> , 2004, 23, 2188-2196.	5.9	43
47	Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. <i>Oncotarget</i> , 2017, 6, e1293213.	4.6	43
48	Molecular biology of the MEN2 gene. <i>Journal of Internal Medicine</i> , 1998, 243, 505-508.	6.0	42
49	Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene. <i>Journal of Biological Chemistry</i> , 2006, 281, 10567-10576.	3.4	42
50	Interleukin-8, but Not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells. <i>Stem Cells</i> , 2017, 35, 135-146.	3.2	40
51	Higher Intratumoral Expression of CD1a, Tryptase, and CD68 in a Follicular Variant of Papillary Thyroid Carcinoma Compared to Adenomas: Correlation with Clinical and Pathological Parameters. <i>Thyroid</i> , 2011, 21, 1209-1215.	4.5	39
52	PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 22.	8.6	37
53	The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma. <i>American Journal of Pathology</i> , 2004, 165, 511-521.	3.8	35
54	CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. <i>Modern Pathology</i> , 2012, 25, 46-55.	5.5	35

#	ARTICLE	IF	CITATIONS
55	Glial Cell Line-Derived Neurotrophic Factor Differentially Stimulates Ret Mutants Associated with the Multiple Endocrine Neoplasia Type 2 Syndromes and Hirschsprung's Disease. <i>Endocrinology</i> , 1998, 139, 3613-3619.	2.8	32
56	OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. <i>British Journal of Cancer</i> , 2007, 97, 1545-1551.	6.4	32
57	New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution. <i>Pharmacological Research</i> , 2018, 128, 80-87.	7.1	31
58	RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors. <i>Oncogene</i> , 2005, 24, 6303-6313.	5.9	30
59	Protein kinase C α activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. <i>Oncogene</i> , 2003, 22, 2942-2949.	5.9	27
60	A New Germline Point Mutation in Ret Exon 8 (Cys ⁵¹⁵ Ser) in a Family with Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2008, 18, 775-782.	4.5	27
61	AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer. <i>Cancers</i> , 2019, 11, 785.	3.7	27
62	Inflammation in thyroid oncogenesis. <i>American Journal of Cancer Research</i> , 2012, 2, 286-97.	1.4	25
63	In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. , 2022, 10, e004032.		25
64	CXC Chemokine Receptor 4 Immunodetection in the Follicular Variant of Papillary Thyroid Carcinoma: Comparison to Galectin-3 and Hector Battifora Mesothelial Cell-1. <i>Thyroid</i> , 2010, 20, 495-504.	4.5	24
65	Multiple anti-tumor effects of Reparixin on thyroid cancer. <i>Oncotarget</i> , 2017, 8, 35946-35961.	1.8	22
66	Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies. <i>F1000Research</i> , 2019, 8, 227.	1.6	20
67	RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2). <i>Endocrine-Related Cancer</i> , 2018, 25, T105-T119.	3.1	19
68	A New Germline RET Mutation Apparently Devoid of Transforming Activity Serendipitously Discovered in a Patient with Atrophic Autoimmune Thyroiditis and Primary Ovarian Failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4810-4816.	3.6	18
69	Molecular Biomarkers in Thyroid FNA Samples. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4370-4373.	3.6	18
70	Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1. <i>Journal of Biological Chemistry</i> , 2017, 292, 1785-1797.	3.4	17
71	Interaction between HMGA1 and Retinoblastoma Protein Is Required for Adipocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2009, 284, 25993-26004.	3.4	16
72	Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27kip 1. <i>Oncogene</i> , 2002, 21, 1739-1749.	5.9	13

#	ARTICLE	IF	CITATIONS
73	Different mutations of the RET gene cause different human tumoral diseases. Biochimie, 1999, 81, 397-402.	2.6	12
74	The genomic landscape of papillary thyroid carcinoma. Nature Reviews Endocrinology, 2015, 11, 133-134.	9.6	12
75	Editorial: Novel Mechanism of Radioactive Iodine Refractivity in Thyroid Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	11
76	Pivotal Role of the RB Family Proteins in in Vitro Thyroid Cell Transformation. Experimental Cell Research, 2000, 260, 257-267.	2.6	10
77	Toll-Like Receptor 7 Mediates Inflammation Resolution and Inhibition of Angiogenesis in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 740.	3.7	8
78	Receptor- and Non-Receptor Tyrosine Kinases Induce Processing of the Amyloid Precursor Protein: Role of the Low-Density Lipoprotein Receptor-Related Protein. Neurodegenerative Diseases, 2007, 4, 94-100.	1.4	7
79	Only the Substitution of Methionine 918 with a Threonine and Not with Other Residues Activates RET Transforming Potential. Endocrinology, 1997, 138, 1450-1455.	2.8	7
80	Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready?. F1000 Medicine Reports, 2010, 2, 62.	2.9	7
81	The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression. Cancers, 2022, 14, 3333.	3.7	6
82	RET: A Multi-Faceted Gene in Human Cancer. Endocrinology and Metabolism, 2012, 27, 173.	3.0	1
83	The RET Receptor Family. , 2015, , 559-591.		1
84	Glial cell line-derived neurotrophic factor (GDNF) stimulates ret activity. Rendiconti Lincei, 1997, 8, 139-149.	2.2	0
85	Genetica molecolare del carcinoma tiroideo differenziato: implicazioni diagnostiche e terapeutiche. L Endocrinologo, 2009, 10, 114-118.	0.0	0
86	FRT â€“ FONDATION RENE TOURAINE. Experimental Dermatology, 2015, 24, 803-820.	2.9	0
87	Molecular Mechanisms of RET Activation in Human Neoplasia. , 2002, , 176-183.		0